Sarepta Therapeutics beats by $0.24, beats on revenue

Sarepta Therapeutics (SRPT): Q1 EPS of -$0.55 beats by $0.24.

Revenue of $6.1M (+36.5% Y/Y) beats by $2.65M.

From other sites
Comments (1)
  • dlmich
    , contributor
    Comment (1) | Send Message
    when are the licensing being completely lifted....why is the price down now?


    the stock mrkt makes no f"ing sense at all. the ones that do good get stomped on and the ones that do poorly get the benefit of the doubt. hate it
    8 May 2014, 02:39 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs